<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04809623</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-497-5888</org_study_id>
    <secondary_id>2021-000204-38</secondary_id>
    <nct_id>NCT04809623</nct_id>
  </id_info>
  <brief_title>Study of GS-5718 in Participants With Cutaneous Lupus Erythematosus (CLE)</brief_title>
  <acronym>LYNX</acronym>
  <official_title>A Randomized, Blinded, Placebo-Controlled, Phase 1b Study of GS-5718 in Subjects With Cutaneous Lupus Erythematosus (CLE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and tolerability of GS-5718 in&#xD;
      participants with Cutaneous Lupus Erythematosus (CLE) with or without Systemic Lupus&#xD;
      Erythematosus (SLE).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing Adverse Events</measure>
    <time_frame>First dose date up to 4 weeks plus 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing Laboratory Abnormalities</measure>
    <time_frame>First dose date up to 4 weeks plus 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameter AUCtau of GS-5718</measure>
    <time_frame>Predose and up to 6 hours postdose at Week 4</time_frame>
    <description>AUCtau is defined as the area under the concentration versus time curve over the dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: Cmax of GS-5718</measure>
    <time_frame>Predose and up to 6 hours postdose at Week 4</time_frame>
    <description>Cmax is defined as the maximum observed concentration of drug.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Cutaneous Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>GS-5718</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GS-5718 orally once daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive placebo orally once daily for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-5718</intervention_name>
    <description>Tablets administered orally</description>
    <arm_group_label>GS-5718</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match GS-5718 tablets administered orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Either fulfill Image result for eular medical abbreviation The European League Against&#xD;
             Rheumatism (EULAR)/ American College of Rheumatology(ACR) 2019 classification criteria&#xD;
             for SLE or have biopsy-proven CLE&#xD;
&#xD;
          -  Must have active acute cutaneous lupus erythematosus (ACLE)/ subacute cutaneous lupus&#xD;
             erythematosus (SCLE); individuals with mixed skin presentations of lupus skin disease&#xD;
             (including DLE) are allowed to enter&#xD;
&#xD;
          -  Cutaneous LE Disease Area and Severity Index (CLASI) activity score of ≥ 6 during&#xD;
             screening and Day 1, excluding the alopecia component&#xD;
&#xD;
          -  Presence of at least 1 representative lupus skin lesion amenable to punch biopsy and&#xD;
             willingness to undergo skin biopsy at 2 time points&#xD;
&#xD;
          -  Protocol-permitted nonbiologic immunosuppressive/immunomodulatory agents for the&#xD;
             treatment of CLE/SLE (eg, antimalarials, methotrexate (MTX), or other conventional&#xD;
             synthetic disease-modifying antirheumatic drug (csDMARDs)) must maintain stable&#xD;
             dose(s) for ≥ 60 days prior to randomization through Week 4 of the study&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Dermatologic disease other than cutaneous manifestations of SLE or CLE that may&#xD;
             interfere with assessment of lupus-specific skin lesions&#xD;
&#xD;
          -  Ongoing or active clinically significant bacterial, fungal or viral infection&#xD;
&#xD;
          -  History of or positive for human immunodeficiency virus, hepatitis C virus, or&#xD;
             hepatitis B virus&#xD;
&#xD;
          -  Uncontrolled health conditions including highly active SLE (e.g. lupus nephritis,&#xD;
             neuropsychiatric SLE, vasculitis etc.)&#xD;
&#xD;
          -  History of malignancy&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Clinical Study Information Center</last_name>
    <phone>1-833-445-3230 (GILEAD-0)</phone>
    <email>GileadClinicalTrials@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wallace Rheumatic Studies Center, LLC</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida, Inc.</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DJL Clinical Research, PLLC</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Metroplex Clinical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 18, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Lupus Erythematosus, Cutaneous</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

